- Report
- October 2023
- 145 Pages
From €2029EUR$2,100USD£1,735GBP
€2898EUR$3,000USD£2,478GBP
- Report
- February 2024
- 94 Pages
Global
From €3500EUR$3,881USD£3,098GBP
- Report
- May 2024
- 50 Pages
Global
From €2560EUR$2,650USD£2,189GBP
- Report
- May 2023
- 74 Pages
Italy
From €3448EUR$3,570USD£2,949GBP
- Report
- February 2024
- 140 Pages
Global
From €5312EUR$5,499USD£4,542GBP
- Report
- September 2023
- 160 Pages
Global
From €2897EUR$2,999USD£2,477GBP
- Report
- July 2023
- 140 Pages
Global
From €5795EUR$5,999USD£4,955GBP
Iodine-131 (I-131) is a radioactive isotope of iodine used in nuclear medicine and radiopharmacology. It is used to diagnose and treat a variety of conditions, including thyroid cancer, hyperthyroidism, and Graves' disease. I-131 is also used to treat certain types of cancer, such as lymphoma and neuroblastoma. It is administered orally, intravenously, or by inhalation. The radiation emitted by I-131 is absorbed by the body and used to destroy cancer cells.
I-131 is produced in nuclear reactors and cyclotrons. It is then purified and formulated into a variety of products, such as capsules, solutions, and suspensions. These products are then distributed to hospitals, clinics, and other healthcare facilities.
The I-131 market is highly regulated, with strict safety and quality standards in place. The market is also subject to fluctuations in supply and demand, as well as changes in the cost of production.
Some companies in the I-131 market include GE Healthcare, Mallinckrodt Pharmaceuticals, Jubilant Radiopharma, and Bracco Diagnostics. Show Less Read more